Related Experiment Videos
Advances in the Immunobiological Therapies for Advanced Melanoma
M C Pérez Gago1, O Saavedra Santa Gadea1, L de la Cruz-Merino1
1Servicio de Oncología Médica, Hospital Universitario Virgen Macarena, Sevilla, España.
Abstract:
Metastatic or locally advanced unresectable melanoma carries a high morbidity and mortality. However, notable advances have been made in recent years in the systemic treatment of this disease, with the appearance of targeted therapy using tyrosine kinase inhibitors that block the mitogen activated protein kinase pathway, and of modern immunotherapy with immune-modulating monoclonal antibodies. In this paper, we provide an update of available data on new immune therapies and we review the clinical development that led to their approval for use in routine clinical practice.
Insights
Recent advances in melanoma treatment include targeted therapies and immunotherapies. This paper reviews new immune therapies and their clinical development for advanced melanoma.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Metastatic or locally advanced unresectable melanoma presents significant morbidity and mortality.
- Recent years have seen major advancements in systemic treatment options for melanoma.
Purpose of the Study:
- To provide an update on novel immune therapies for melanoma.
- To review the clinical development and approval of these new therapies for clinical practice.
Main Methods:
- Review of available data on new immune therapies.
- Analysis of clinical development pathways for approved treatments.
Main Results:
- Significant progress in systemic treatment of advanced melanoma.
- Emergence of targeted therapies (tyrosine kinase inhibitors) and immunotherapies (immune-modulating monoclonal antibodies).
Conclusions:
- New immune therapies represent a notable advance in melanoma treatment.
- Understanding the clinical development is crucial for integrating these therapies into routine practice.